ArticleJournal of virology2006
Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.
Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 72 citations in OpenAlex.
- The purinergic receptor P2X7 as a modulator of viral vector-mediated antigen cross-presentation.Frontiers in immunology · 2024Article
- The poxvirus F17 protein counteracts mitochondrially orchestrated antiviral responses.Nature communications · 2023Article
- Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice.Vaccines · 2023Article
- Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA).Cell death & disease · 2021Article
- Vaccinia Virus Infection Inhibits Skin Dendritic Cell Migration to the Draining Lymph Node.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.Journal of virology · 2019Article
- Modified Vaccinia Virus Ankara Can Induce Optimal CD8Journal of virology · 2019Article
- Ectromelia virus induces tubulin cytoskeletal rearrangement in immune cells accompanied by a loss of the microtubule organizing center and increased α-tubulin acetylation.Archives of virology · 2019Article
- Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.Journal of virology · 2018Article
- Virulent Poxviruses Inhibit DNA Sensing by Preventing STING Activation.Journal of virology · 2018Article
- Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome.Journal of virology · 2017Article
- Functional paralysis of GM-CSF-derived bone marrow cells productively infected with ectromelia virus.PloS one · 2017Article
- Extracellular Virions: The Advance Guard of Poxvirus Infections.PLoS pathogens · 2015Review
- Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination.Journal of virology · 2014Article
- Langerin+ dermal DC, but not Langerhans cells, are required for effective CD8-mediated immune responses after skin scarification with vaccinia virus.The Journal of investigative dermatology · 2014Article
- Article
- The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.The Journal of clinical investigation · 2012Article
- Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.Journal of virology · 2012Article
- Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.PloS one · 2012Article
- Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Modified vaccinia virus Ankara (MVA) is an attenuated strain of vaccinia virus (VV) that has attracted significant attention as a candidate viral vector vaccine for immunization against infectious diseases and treatment of malignancies. Although MVA is unable to replicate in most nonavian cells, vaccination with MVA elicits immune responses that approximate those seen after the administration of replication-competent strains of VV. However, the mechanisms by which these viruses elicit immune responses and the determinants of their relative immunogenicity are incompletely understood. Studying the interactions of VV and MVA with cells of the human immune system may elucidate these mechanisms, as well as provide a rational basis for the further enhancement of the immunogenicity of recombinant MVA vectors. Toward this end, we investigated the consequences of MVA or VV infection of human dendritic cells (DCs), key professional antigen-presenting cells essential for the generation of immune responses. We determined that a block to the formation of intracellular viral replication centers results in abortive infection of DCs with both VV and MVA. MVA inhibited cellular protein synthesis more rapidly than VV and displayed a distinct pattern of viral protein expression in infected DCs. MVA also induced apoptosis in DCs more rapidly than VV, and DC apoptosis after MVA infection was associated with an accelerated decline in the levels of intracellular Bcl-2 and Bcl-X(L). These findings suggest that antigen presentation pathways may contribute differentially to the immunogenicity of VV and MVA and that targeted modifications of virus-induced DC apoptosis may further increase the immunogenicity of MVA-vectored vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.